Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements - Assets and Liabilities at Fair Value (Details)

v3.20.2
Fair Value Measurements - Assets and Liabilities at Fair Value (Details)
1 Months Ended 3 Months Ended
Jan. 31, 2010
contingentValueRight
contingentValueRightSeries
Sep. 30, 2020
USD ($)
Jun. 30, 2020
USD ($)
Dec. 31, 2019
USD ($)
Assets:        
Short-term investments, excluding Viking   $ 297,704,000   $ 939,989,000
Investment in Viking common stock   33,869,000   48,425,000
Investment in warrants   6,581,000   9,910,000
Total assets   338,154,000   998,324,000
Liabilities:        
Amounts owed to former licensor   71,000   75,000
Total liabilities   10,869,000   9,017,000
Repayments of related party debt     $ 1,800,000  
Number of CVR Series | contingentValueRightSeries 4      
Metabasis        
Liabilities:        
Number of CVRs issued per acquiree share | contingentValueRight 4      
Number of CVRs issued from each CVR series | contingentValueRight 1      
Frequency of cash payments to CVR holders 6 months      
Transferred over Time | Phase 3 Clinical Trial        
Liabilities:        
Contract asset   10,000,000    
Maximum | Transferred over Time | Development, Regulatory, & Commercial Milestones and Tiered Royalties        
Liabilities:        
Investments   375,000,000    
Crystal contingent liabilities        
Liabilities:        
Contingent liabilities   800,000   2,659,000
CyDex contingent liabilities        
Liabilities:        
Contingent liabilities   509,000   348,000
Metabasis contingent liabilities        
Liabilities:        
Contingent liabilities   4,985,000   5,935,000
Icagen contingent liabilities        
Liabilities:        
Contingent liabilities   4,504,000   0
Payment for contingent liability   500,000    
Level 1        
Assets:        
Short-term investments, excluding Viking   2,274,000   3,073,000
Investment in Viking common stock   33,869,000   48,425,000
Investment in warrants   6,581,000   9,910,000
Total assets   42,724,000   61,408,000
Liabilities:        
Amounts owed to former licensor   71,000   75,000
Total liabilities   71,000   75,000
Level 1 | Crystal contingent liabilities        
Liabilities:        
Contingent liabilities   0   0
Level 1 | CyDex contingent liabilities        
Liabilities:        
Contingent liabilities   0   0
Level 1 | Metabasis contingent liabilities        
Liabilities:        
Contingent liabilities   0   0
Level 1 | Icagen contingent liabilities        
Liabilities:        
Contingent liabilities   0   0
Level 2        
Assets:        
Short-term investments, excluding Viking   295,275,000   936,791,000
Investment in Viking common stock   0   0
Investment in warrants   0   0
Total assets   295,275,000   936,791,000
Liabilities:        
Amounts owed to former licensor   0   0
Total liabilities   4,985,000   5,935,000
Level 2 | Crystal contingent liabilities        
Liabilities:        
Contingent liabilities   0   0
Level 2 | CyDex contingent liabilities        
Liabilities:        
Contingent liabilities   0   0
Level 2 | Metabasis contingent liabilities        
Liabilities:        
Contingent liabilities   4,985,000   5,935,000
Level 2 | Icagen contingent liabilities        
Liabilities:        
Contingent liabilities   0   0
Level 3        
Assets:        
Short-term investments, excluding Viking   155,000   125,000
Investment in Viking common stock   0   0
Investment in warrants   0   0
Total assets   155,000   125,000
Liabilities:        
Amounts owed to former licensor   0   0
Total liabilities   5,813,000   3,007,000
Level 3 | Crystal contingent liabilities        
Liabilities:        
Contingent liabilities   800,000   2,659,000
Level 3 | CyDex contingent liabilities        
Liabilities:        
Contingent liabilities   509,000   348,000
Level 3 | Metabasis contingent liabilities        
Liabilities:        
Contingent liabilities   0   0
Level 3 | Icagen contingent liabilities        
Liabilities:        
Contingent liabilities   $ 4,504,000   $ 0